Manifold MarketsNo KYCVerified resolution dataFairly calibratedCurrent community forecastYes 82.6%
Forecasters
6
Question type
binary
Methodology
Play-money forecasting platform
Source type
Forecast
Market data
Updated 18 hours ago
StaleJun 29, 25, 6:02 PM UTCDec 31, 26, 11:59 PM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
Manifold MarketsWill Lantern Bioworks Lumina treatment be FDA Approved for preventing tooth decay by the end of 2026?
Manifold MarketsWill Lantern Bioworks Lumina treatment be FDA Approved for preventing tooth decay by the end of 2028?
Manifold MarketsRaniPill microneedle pill to replace injections: approved for sale by the end of 2026?
FutuurTdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
FutuurWill 3 mg THC beverages be federally legal to sell?
KalshiRules
This market predicts whether any myostatin inhibitor will receive regulatory approval for any condition by December 31, 2026.
- Myostatin inhibitors are being developed to treat conditions like muscular dystrophy and obesity.
- Notable candidates include Regeneron's trevogrumab and Eli Lilly's bimagrumab.
- Approval status can be verified through official regulatory agency announcements, such as those from the FDA (https://www.fda.gov/).
Frequently asked questions
- What are the current odds for Any myostatin inhibitor FDA approved by 2027?
- Manifold Markets prices Yes at 83% as of September 8, 2026.
- When does Any myostatin inhibitor FDA approved by 2027 resolve?
- Any myostatin inhibitor FDA approved by 2027 is scheduled to resolve on December 31, 2026.
- How is Any myostatin inhibitor FDA approved by 2027 settled?
- Manifold Markets settles this market as follows: This market predicts whether any myostatin inhibitor will receive regulatory approval for any condition by December 31, 2026.
